ArticleBMC cancer2026
A mobile health app for real-time symptom monitoring in patients with cancer during COVID-19: feasibility, acceptability, and utility.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04397614 (Mobile Health Study and Enhanced Symptom Monitoring to Prevent Severe Illness From COVID-19 in Cancer Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mobile Health Study and Enhanced Symptom Monitoring to Prevent Severe Illness From COVID-19 in Cancer Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPatients undergoing cancer treatment often endure significant symptom burden, necessitating timely management to prevent severe complications. The COVID-19 pandemic highlighted the need for real-time remote symptom monitoring, particularly for cancer patients at heightened risk due to immunosuppression from cancer and chemotherapy.
methodsThis 24-week, single-arm intervention study was conducted from July 2020 to May 2021 at the Stephenson Cancer Center Infusion Clinic in Oklahoma, USA. This study assessed the feasibility, acceptability, and utility of the Symptom Tracker smartphone app. The app prompted 128 patients receiving cytotoxic chemotherapy to report symptoms associated with cancer, cancer treatment, and COVID-19. Reports indicating elevated COVID-19 risk automatically triggered notifications to nursing staff for follow-up and testing. Primary outcomes included daily symptom reporting adherence and patient satisfaction.
resultsParticipants (N = 128) had a mean age of 57.6 years (SD = 13.0), with 77.3% being female. Approximately 10,000 daily symptom reports were completed, representing 46% of all study days. The app facilitated 302 patient-initiated contacts with cancer treatment staff. During the study period, seven participants (5.5%) tested positive for COVID-19 and were successfully triaged. Weekly feedback revealed that 76.8%-89.1% of participants considered the frequency of assessments “about right.”
conclusionThe Symptom Tracker app demonstrated feasibility, acceptability, and utility, as evidenced by high symptom reporting adherence, user satisfaction, and effective remote symptom management across a diverse patient population in Oklahoma. Our approach shows promise for supporting oncology care, enhancing real-time monitoring of symptom variability, and ensuring rapid response to critical symptoms.
trial registrationClinicalTrials.gov Identifier: NCT04397614, Registration date: May 22, 2020.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.